A smallish acquisition to report Tuesday morning: Ireland-based specialty drug maker Mallinckrodt is buying Cadence Pharmaceuticals (CADX) for $14 per share, or a 27% premium over Monday's close. The total cost of the acquisition is $1.3 billion.
Cadence's lead product is Ofirmev, an intravenous formulation of the painkiller acetaminophen used to treat hospitalized patients. Ofirmev sales in 2013 were $110.5 million, Cadence announced last month. The Street expects 2014 Ofirmev sales of $168 million.
"The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company," said Mallinckrodt CEO Mark Trudeau, in a statement.
Mallinckrodt expects the Cadence acquisition to be accretive to fiscal year 2014 earnings on an adjusted basis. The deal is expected to close in March.
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/05/15 - 10:40 AM EDT
08/27/15 - 08:32 AM EDT
08/26/15 - 08:51 AM EDT
08/25/15 - 08:35 AM EDT
08/25/15 - 08:31 AM EDT
08/24/15 - 08:35 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.